Characterizing the phenotype of multiple sclerosis–associated depression in comparison with idiopathic major depression

Hasselmann, Helge; Bellmann‐Strobl, Judith; Ricken, Roland; Oberwahrenbrock, Timm; Rose, Matthias; Otte, Christian; Adli, Mazda; Paul, Friedemann; Brandt, Alexander U.; Finke, Carsten; Gold, Stefan M.

doi:10.1177/1352458515622826

Cited by 33 publications

(16 citation statements)

References 35 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to previous reports, we demonstrated that a fraction of the association between depression and HRQoL is mediated through fatigue . It has also been reported that the contribution of fatigue to depression severity in patients with MS is higher than in idiopathic depressive disorder . Fatigue is not only associated with patient‐reported HRQoL in cross‐sectional and longitudinal analyses, but it is also a predictor of disease activity and progression in patients with CIS and MS .…”

Section: Discussionmentioning

confidence: 96%

Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study

Nourbakhsh

Julián

Waubant

2016

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study

Nourbakhsh

Julián

Waubant

2016

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…In addition, the NEDA concept has been heavily criticized because of ignoring other relevant and disabling symptoms of the disease, such as fatigue, cognitive problems, sleep disorders, depression, etc. (71, [99][100][101][102][103][104][105][106][107][108][109]. Moreover, recent safety concerns as to the deposition of gadolinium-based contrast agents (predominantly linear compounds) in the dentate nucleus and other brain regions provide arguments against their frequent use in monitoring radiographic disease activity in otherwise stable patients (110)(111)(112)(113).…”

Section: Multiple Sclerosismentioning

confidence: 99%

Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

Kuchling

Paul

2020

Front. Neurol.

Self Cite

View full text Add to dashboard Cite

“…25 Omitting overlapping somatic symptoms from rating scales for depression has been proposed, 26 but examined more closely the clinical depression phenotype does not differ very much between MS patients and other depressed patients. 27 Still, in magnetic resonance imaging (MRI) studies, a structural basis seems to exist for depression in MS and could explain up to 42% of depression variance.…”

mentioning

confidence: 99%

Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions

Brenner

Piehl

2016

Acta Neurol Scand

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a neuroinflammatory condition with a prominent progressive neurodegenerative facet that typically affects young-or middle-aged adults. Although physical disabilities have been in the foreground by being easier to assess, there is an increasing interest in mental disabilities and psychiatric co-morbidities, which have a disproportionally high impact on important outcome measures such as quality of life and occupational disability. In particular, cognitive impairment, depression and mental fatigue, which mutually interact with each other, seem to be of importance in this context. In recent decades, major efforts have been invested in developing more effective disease modulatory treatments. This has resulted in novel therapeutic options and awareness of the importance of early intervention. In comparison, good quality and adequately powered studies on symptomatic treatments of fatigue and psychiatric co-morbidities in MS are rare, and awareness of treatment options is much lower. We here review the existing evidence base for symptomatic treatment of fatigue and depression in MS patients. With regard to fatigue, off-label prescription of alertness improving drugs is common, in spite of all but absent evidence of efficacy. In contrast, a number of smaller studies suggest that physical exercise and fatigue management courses may have some clinical benefit. Very few studies have addressed the efficacy of antidepressants and non-pharmaceutical interventions specifically in MS patients. Therefore, treatment guidelines largely rely on data from non-MS populations. In the future, there is a strong motive to direct additional resources to the study of these important aspects of MS. K E Y W O R D Scognitive symptoms, depression, fatigue, multiple sclerosis, treatment

show abstract

Characterizing the phenotype of multiple sclerosis–associated depression in comparison with idiopathic major depression

Abstract: The clinical phenotype of "idiopathic" MDD and MS-associated depression appears similar when adequately examined. The relevance of these findings for psychotherapeutic approaches for MS-associated depression should be explored in future studies.

Cited by 33 publications

References 35 publications

Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study

Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study

Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions

Contact Info

Product

Resources

About